| 1 |
Lingvay I, Mosenzon O, Brown K, Cui X, O'Neill C, Fernández Landó L, Patel H. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol 2023;22:66. [PMID: 36964557 DOI: 10.1186/s12933-023-01797-5] [Reference Citation Analysis]
|
| 2 |
Verde L, Lucà S, Cernea S, Sulu C, Yumuk VD, Jenssen TG, Savastano S, Sarno G, Colao A, Barrea L, Muscogiuri G. The Fat Kidney. Curr Obes Rep 2023. [PMID: 36933154 DOI: 10.1007/s13679-023-00500-9] [Reference Citation Analysis]
|
| 3 |
Frías JP. An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program. Expert Rev Endocrinol Metab 2023;:1-20. [PMID: 36908082 DOI: 10.1080/17446651.2023.2184796] [Reference Citation Analysis]
|
| 4 |
Mima A, Gotoda H, Lee R, Murakami A, Akai R, Lee S. Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis. Metabol Open 2023;17:100236. [PMID: 36923991 DOI: 10.1016/j.metop.2023.100236] [Reference Citation Analysis]
|
| 5 |
Morgenroth R, Mertens PR, Herzog C, Scurt FG. Therapieoptionen bei diabetischer Nephropathie. Diabetologie 2023. [DOI: 10.1007/s11428-023-01003-w] [Reference Citation Analysis]
|
| 6 |
Thomas MC, Coughlan MT, Cooper ME. The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes. Cell Metab 2023;35:253-73. [PMID: 36754019 DOI: 10.1016/j.cmet.2023.01.004] [Reference Citation Analysis]
|
| 7 |
Typ-2-Diabetes: Tirzepatid stoppt Abnahme der Nierenfunktion. Diabetologie und Stoffwechsel 2023;18:23-24. [DOI: 10.1055/a-1933-5801] [Reference Citation Analysis]
|
| 8 |
Jin T. Tirzepatide, a new class of incretin-based drug for diabetes. Obesity Medicine 2023. [DOI: 10.1016/j.obmed.2023.100483] [Reference Citation Analysis]
|
| 9 |
Sattar N, Deanfield J, Delles C. Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes? Cardiovasc Res 2023:cvac186. [PMID: 36683167 DOI: 10.1093/cvr/cvac186] [Reference Citation Analysis]
|
| 10 |
Scheen AJ. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes. Ann Endocrinol (Paris) 2023:S0003-4266(23)00004-5. [PMID: 36639119 DOI: 10.1016/j.ando.2022.12.423] [Reference Citation Analysis]
|
| 11 |
Zaffina I, Pelle MC, Armentaro G, Giofrè F, Cassano V, Sciacqua A, Arturi F. Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity. Front Endocrinol (Lausanne) 2023;14:1095753. [PMID: 36909312 DOI: 10.3389/fendo.2023.1095753] [Reference Citation Analysis]
|
| 12 |
Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G. Tirzepatide: A Systematic Update. Int J Mol Sci 2022;23. [PMID: 36498958 DOI: 10.3390/ijms232314631] [Reference Citation Analysis]
|
| 13 |
Solini A. Tirzepatide and kidney function: an intriguing and promising observation. Lancet Diabetes Endocrinol 2022;10:762-3. [PMID: 36152638 DOI: 10.1016/S2213-8587(22)00258-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Bulum T. Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists. Biomedicines 2022;10:2586. [PMID: 36289848 DOI: 10.3390/biomedicines10102586] [Reference Citation Analysis]
|
